

Resource Summary Report

Generated by [dkNET](#) on Aug 27, 2026

Hamamatsu: NanoZoomer S210 Digital slide scanner

RRID:SCR_023760

Type: Tool

Proper Citation

Hamamatsu: NanoZoomer S210 Digital slide scanner (RRID:SCR_023760)

Resource Information

URL: <https://www.hamamatsu.com/jp/en/product/life-science-and-medical-systems/digital-slide-scanner/C13239-01.html>

Proper Citation: Hamamatsu: NanoZoomer S210 Digital slide scanner (RRID:SCR_023760)

Description: NanoZoomer series is family of whole slide scanners that rapidly scan glass slides to convert them to digital data. NanoZoomer S210 provides high performance capable of handling large number of slides.

Synonyms: NanoZoomer S210 Digital slide scanner

Resource Type: instrument resource

Keywords: USEDit, Hamamotsu, whole slide scanner, glass slides, large number of slides

Availability: Restricted

Specification URL: https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/main/PDF/SCR_023760.pdf

Resource Name: Hamamatsu: NanoZoomer S210 Digital slide scanner

Resource ID: SCR_023760

Record Creation Time: 20230708T050227+0000

Record Last Update: 20260815T182738+0000

Ratings and Alerts

No rating or validation information has been found for Hamamatsu: NanoZoomer S210 Digital slide scanner.

No alerts have been found for Hamamatsu: NanoZoomer S210 Digital slide scanner.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Mesropian A, et al. (2025) E7386 Enhances Lenvatinib's Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(23), 5037.

Chan KK, et al. (2025) Secreted lumican from the tumor microenvironment potentiates HCC stemness and progression. Hepatology communications, 9(9).

Zhu XZ, et al. (2025) Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2- Breast Cancer. Cancer research, 85(20), 3983.